2104 related articles for article (PubMed ID: 33121495)
1. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
2. Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression.
Du C; Lv C; Feng Y; Yu S
J Exp Clin Cancer Res; 2020 Oct; 39(1):223. PubMed ID: 33087165
[TBL] [Abstract][Full Text] [Related]
3. Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells.
Chen Y; Pan C; Wang X; Xu D; Ma Y; Hu J; Chen P; Xiang Z; Rao Q; Han X
Theranostics; 2021; 11(16):7640-7657. PubMed ID: 34335955
[No Abstract] [Full Text] [Related]
4. m
Lang C; Yin C; Lin K; Li Y; Yang Q; Wu Z; Du H; Ren D; Dai Y; Peng X
Clin Transl Med; 2021 Jun; 11(6):e426. PubMed ID: 34185427
[TBL] [Abstract][Full Text] [Related]
5. YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m
Chai RC; Chang YZ; Chang X; Pang B; An SY; Zhang KN; Chang YH; Jiang T; Wang YZ
J Hematol Oncol; 2021 Jul; 14(1):109. PubMed ID: 34246306
[TBL] [Abstract][Full Text] [Related]
6. m
Shen C; Xuan B; Yan T; Ma Y; Xu P; Tian X; Zhang X; Cao Y; Ma D; Zhu X; Zhang Y; Fang JY; Chen H; Hong J
Mol Cancer; 2020 Apr; 19(1):72. PubMed ID: 32245489
[TBL] [Abstract][Full Text] [Related]
7. METTL3 facilitates tumor progression via an m
Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
[TBL] [Abstract][Full Text] [Related]
8. METTL3/YTHDF2 m
Xie H; Li J; Ying Y; Yan H; Jin K; Ma X; He L; Xu X; Liu B; Wang X; Zheng X; Xie L
J Cell Mol Med; 2020 Apr; 24(7):4092-4104. PubMed ID: 32126149
[TBL] [Abstract][Full Text] [Related]
9. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer.
Chen X; Xu M; Xu X; Zeng K; Liu X; Pan B; Li C; Sun L; Qin J; Xu T; He B; Pan Y; Sun H; Wang S
Mol Cancer; 2020 Jun; 19(1):106. PubMed ID: 32552762
[TBL] [Abstract][Full Text] [Related]
10. m
Jin D; Guo J; Wu Y; Du J; Yang L; Wang X; Di W; Hu B; An J; Kong L; Pan L; Su G
J Hematol Oncol; 2019 Dec; 12(1):135. PubMed ID: 31818312
[TBL] [Abstract][Full Text] [Related]
11. METTL3 Modulates Osteoclast Differentiation and Function by Controlling RNA Stability and Nuclear Export.
Li D; Cai L; Meng R; Feng Z; Xu Q
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32121289
[TBL] [Abstract][Full Text] [Related]
12. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.
Niu Y; Lin Z; Wan A; Chen H; Liang H; Sun L; Wang Y; Li X; Xiong XF; Wei B; Wu X; Wan G
Mol Cancer; 2019 Mar; 18(1):46. PubMed ID: 30922314
[TBL] [Abstract][Full Text] [Related]
13. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST.
Yang X; Zhang S; He C; Xue P; Zhang L; He Z; Zang L; Feng B; Sun J; Zheng M
Mol Cancer; 2020 Feb; 19(1):46. PubMed ID: 32111213
[TBL] [Abstract][Full Text] [Related]
14. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
Chen M; Wei L; Law CT; Tsang FH; Shen J; Cheng CL; Tsang LH; Ho DW; Chiu DK; Lee JM; Wong CC; Ng IO; Wong CM
Hepatology; 2018 Jun; 67(6):2254-2270. PubMed ID: 29171881
[TBL] [Abstract][Full Text] [Related]
15. METTL3-dependent N
Chien CS; Li JY; Chien Y; Wang ML; Yarmishyn AA; Tsai PH; Juan CC; Nguyen P; Cheng HM; Huo TI; Chiou SH; Chien S
Proc Natl Acad Sci U S A; 2021 Feb; 118(7):. PubMed ID: 33579825
[TBL] [Abstract][Full Text] [Related]
16. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
Guo X; Li K; Jiang W; Hu Y; Xiao W; Huang Y; Feng Y; Pan Q; Wan R
Mol Cancer; 2020 May; 19(1):91. PubMed ID: 32429928
[TBL] [Abstract][Full Text] [Related]
17. METTL3-Mediated m
Mao Y; Li W; Weng Y; Hua B; Gu X; Lu C; Xu B; Xu H; Wang Z
Cell Transplant; 2022; 31():9636897221122997. PubMed ID: 36073002
[TBL] [Abstract][Full Text] [Related]
18. METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m
Xu QC; Tien YC; Shi YH; Chen S; Zhu YQ; Huang XT; Huang CS; Zhao W; Yin XY
Oncogene; 2022 Mar; 41(11):1622-1633. PubMed ID: 35094011
[TBL] [Abstract][Full Text] [Related]
19. METTL3-mediated m6A modification of pri-miR-148a-3p affects prostate cancer progression by regulating TXNIP.
Li G; Liu J; Wang Y; Liu H; Fu J; Zhao Y; Huang Y
Environ Toxicol; 2023 Oct; 38(10):2377-2390. PubMed ID: 37449729
[TBL] [
